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LDL receptor-related protein-1 (LRP1) is an endocytic and cell-
signaling receptor. In mice in which LRP1 is deleted in myeloid
cells, the response to lipopolysaccharide (LPS) was greatly exacer-
bated. LRP1 deletion in macrophages in vitro, under the control of
tamoxifen-activated Cre-ERT fusion protein, robustly increased ex-
pression of proinflammatory cytokines and chemokines. In LRP1-
expressing macrophages, proinflammatory mediator expression
was regulated by LRP1 ligands in a ligand-specific manner. The
LRP1 agonists, α2-macroglobulin and tissue-type plasminogen ac-
tivator, attenuated expression of inflammatory mediators, even in
the presence of LPS. The antagonists, receptor-associated protein
(RAP) and lactoferrin (LF), and LRP1-specific antibody had the en-
tirely opposite effect, promoting inflammatory mediator expres-
sion and mimicking LRP1 deletion. NFκB was rapidly activated in
response to RAP and LF and responsible for the initial increase in
expression of proinflammatory mediators. RAP and LF also signif-
icantly increased expression of microRNA-155 (miR-155) after a lag
phase of about 4 h. miR-155 expression reflected, at least in part,
activation of secondary cell-signaling pathways downstream of
TNFα. Although miR-155 was not involved in the initial induction of
cytokine expression in response to LRP1 antagonists, miR-155 was es-
sential for sustaining the proinflammatory response. We conclude that
LRP1, NFκB, and miR-155 function as members of a previously uniden-
tified system that has the potential to inhibit or sustain inflammation,
depending on the continuum of LRP1 ligands present in the
macrophage microenvironment.
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Innate immunity is a phylogenetically conserved system thatprovides a first line of defense against pathogens (1, 2). Pattern
recognition receptors (PRRs), including members of the Toll-
like receptor (TLR) family, play an important role in innate
immunity, binding microorganism-derived molecules, and initi-
ating proinflammatory cell signaling (1, 3, 4). The effector sys-
tems of innate immunity, including proinflammatory cytokines
and complement, may be very potent and when regulatory
mechanisms fail, shock and death may result (3). Diverse diseases
are exacerbated by dysregulated innate immunity, including Crohn’s
disease, rheumatoid arthritis, asthma, psoriasis, atherosclerosis, and
cancer (3, 5, 6). Understanding mechanisms that control innate
immunity is a significant problem in medicine.
LDL receptor-related protein-1 (LRP1) is an endocytic and
cell-signaling receptor, which is essential for embryonic devel-
opment (7, 8). In adults, there is increasing evidence that LRP1
regulates inflammation (9). LRP1-deficient macrophages, isolated
from mice in which LRP1 is conditionally deleted in myeloid cells
(mLRP1−/− mice), express increased levels of proinflammatory
chemokines, including monocyte chemotactic protein/CCL2, MIP-
1α/CCL3, and MIP-1β/CCL4 (10–12). These macrophages also
migrate more rapidly, due to activation of CCL3-CCR5 signaling
(10) and express decreased levels of biomarkers associated with
M2 polarization (13).
In syngeneic tumors in mLRP1−/− mice, LRP1-deficient macro-
phages accumulate in increased number and express increased levels
of CCL3 (10). Macrophage infiltration is also increased in athero-
sclerotic lesions in mLRP1−/− mice (11). However, mechanisms by
which LRP1 regulates macrophage physiology remain incompletely
understood. LRP1 deficiency is associated with increased NFκB
activity in passaged cell lines (12); however, “loss of function”model
systems do not address the role of LRP1 as a receptor for diverse
ligands (7, 14). In neurons and neuron-like cells, different LRP1
ligands elicit distinct cell-signaling responses by engaging separate
LRP1 coreceptors (15–17). If LRP1 regulates macrophage physi-
ology in a ligand-specific manner, this would represent a powerful
mechanism by which macrophages may respond to changes in
their microenvironment.
In this study, we challenged mLRP1−/− mice and control
mLRP1+/+ mice with lipopolysaccharide (LPS), which is a major
ligand for the PRR, TLR4 (18). The response to LPS was greatly
exacerbated in mLRP1−/− mice. Using a second genetic model
system, we confirmed that LRP1 gene deletion in macrophages
increases expression of proinflammatory mediators. We then
showed that expression of proinflammatory mediators is con-
trolled in macrophages by LRP1 ligands in a ligand-specific
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manner. LRP1 agonists, such as α2-macroglobulin (α2M) and
tissue-type plasminogen activator (tPA), suppressed expression
of proinflammatory mediators, even in the presence of LPS.
Antagonists, such as receptor-associated protein (RAP) and
lactoferrin (LF), increased expression of the identical media-
tors, mimicking the effects of LRP1 gene deletion. The activity
of LRP1 ligands was linked to regulation of NFκB and the
previously unreported ability of LRP1 to control expression of
microRNA-155 (miR-155) (19). LRP1, NFκB, and miR-155
emerge as members of a novel system that may control the
macrophage inflammatory response in a microenvironment-
sensitive manner.
Results
The Response to LPS Is Exacerbated in mLRP1−/− Mice. In mLRP1−/−
mice, LRP1 is deleted in cells in which the lysozyme-M (LysM)
promoter is active, including monocytes, macrophages, neutro-
phils, and to some extent, dendritic cells (20). mLRP1+/+ mice
are homozygous for the floxed LRP1 gene but LysM-Cre-nega-
tive (21). Although LRP1 has been identified in neutrophils (22),
its function in these cells is not well studied. By contrast, LRP1 is
a known regulator of monocytes and macrophages (9). In the
absence of experimental immune system challenge, we did not
identify abnormal inflammation in 12-wk-old mLRP1−/− mice.
TNFα and CCL3 were nearly undetectable by ELISA in plasma
from mLRP1−/− mice. In the lungs of mLRP1−/− mice, myeloid
cells were restricted mainly to interstitial spaces and unchanged in
abundance compared with mLRP1+/+ mice, as determined by
CD11b immunohistochemistry (IHC) (Fig. 1A) and image analysis.
mLRP1−/− and mLRP1+/+ mice were injected i.p. with LPS
(n = 10–11) or vehicle. The LPS dose was set at 50% of the
LD50 to optimize our opportunity to detect increased sensitivity.
No toxicity or mortality was observed in vehicle-treated controls,
as anticipated (Fig. 1B). One mLRP1+/+ mouse succumbed to
LPS. By contrast, 80% of the mLRP1−/− mice succumbed within
24 h of LPS injection. The increase in mortality of LPS-treated
mLRP1−/− mice, compared with mLRP1+/+ mice, was statisti-
cally significant as determined by log-rank test (P < 0.001).
Plasma was sampled 0, 3, 6, and 24 h after LPS injection.
TNFα protein was increased in plasma from mLRP1−/− mice,
compared with mLRP1+/+ mice, at 3 and 6 h (Fig. 1C). CCL3
was also increased at 3 and 6 h (Fig. 1D). Quantitative reverse
transcription–PCR (RT-qPCR) was performed to assess ex-
pression of proinflammatory genes in tissues harvested 24 h after
injecting LPS or vehicle. IL-6 and inducible nitric oxide synthase
(iNOS) mRNA were significantly increased in the lungs (Fig. 1 E
and F) and kidneys (Fig. 1 G and H) of LPS-treated mLRP1−/−
mice, compared with mLRP1+/+ mice. In vehicle-treated
mLRP1−/− and mLRP1+/+ mice, IL-6 and iNOS mRNA were not
significantly different, again indicating that significant in-
flammation is not present under basal conditions in mLRP1−/−
mice.
Analysis of a Second Model of LRP1 Gene Deletion in Macrophages. In
mLRP1−/− mice, LRP1 is deleted during development (10, 11),
allowing for compensatory changes in the physiology of these
cells. To address this issue, we generated homozygous LRP1flox/flox
mice that express tamoxifen (TAM)-activated Cre-fusion protein
(Cre-ERT) (23). Bone-marrow–derived macrophages (BMDMs)
were isolated and LRP1 protein expression was studied. Fig. 2A
shows that, in the absence of TAM, Cre-ERT-positive and -negative
BMDMs expressed similar levels of LRP1. After treatment with
5 μM TAM for 7 d, LRP1 protein expression was neutralized in
Cre-ERT-positive cells and unchanged in Cre-ERT-negative cells.
When LRP1 was deleted in Cre-ERT-positive BMDMs, ex-
pression of TNFα, IL-6, IL-1β, CCL2, and CCL3 was increased
(Fig. 2 B–F). TAM did not affect cytokine expression in Cre-ERT-
negative cells. LRP1 gene deletion also stimulated cell migration
(P < 0.001) (Fig. 2 G and H), mimicking the results obtained
with BMDMs from mLRP1−/− mice (10). TAM-induced LRP1
gene deletion did not increase apoptosis, determined 8 h after
transferring cells to serum-free medium (SFM), or alter the
number of viable cells, determined by trypan blue exclusion at 24 h
(Fig. S1).
LRP1 Ligands Regulate Macrophage Physiology in a Ligand-Specific
Manner. In neurons and neuron-like cells, α2M* and tPA function
as LRP1 agonists, activating cell-signaling factors such as c-Src,
ERK1/2, and Akt (15–17). LF and RAP function as antagonists,
blocking cell signaling in response to agonists (16). We treated
BMDMs from wild-type C57BL/6J mice with RAP (150 nM),
LF (150 nM), or LPS (0.1 μg/mL) for 8 h. Fig. 3 A–C shows that
RAP and LF increased expression of TNFα, IL-6, and CCL2
mRNA, similarly to LPS. RAP and LF also increased expression
of IL-1β and CCL4 (Fig. S2 A and B). Fig. 3D shows that RAP
increased CCL3 mRNA in a dose-dependent manner; 10 nM
RAP was sufficient to induce a significant response. RAP and
LF also increased TNFα protein levels in BMDM-conditioned
medium, similarly to LPS (Fig. 3E).
RAP and LF stimulated BMDM cell migration (Fig. 3 F and
G), mimicking the effects of LRP1 gene deletion (10). Although
inflammatory mediators are known to decrease LRP1 protein
Fig. 1. LPS toxicity is increased in mice in which LRP1 is deleted in myeloid
cells. (A) IHC was performed to detect CD11b-positive myeloid cells in sec-
tions of lung from untreated mLRP1+/+ and mLRP1−/−mice. (Scale bar, 100 μm.)
Image analysis did not reveal a difference in the density of CD11b-positive cells
(n = 3). (B) Kaplan–Meier survival curves are shown for mLRP1−/− and mLRP1+/+
mice treated by i.p. injection with 1 mg/kg LPS or vehicle (Veh). Significance was
determined by log-rank test (***P < 0.001). (C and D) ELISAs were performed to
detect TNFα and CCL3 in plasma samples harvested at the indicated times from
LPS-treated mLRP1−/− (blue bar) and mLRP1+/+ (red bar) mice (mean ± SEM; n =
10; *P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA with Tukey’s post hoc
analysis). (E–H) RNA was harvested from the lungs (E and F) and kidneys (G and
H) of mLRP1+/+ and mLRP1−/−mice 24 h after i.p. injection of LPS or vehicle (C).
IL-6 and iNOS mRNA were determined by RT-qPCR (n = 4).
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levels in macrophages (24, 25), LRP1 protein was unchanged in
BMDMs treated with LF or RAP for 8 h (Fig. 3H). Modest
changes in LRP1 mRNA were observed in cells treated for 8 h
with LF (44 ± 6%) or RAP (52 ± 5%), suggesting that longer
incubations may have decreased the LRP1 protein level.
We hypothesized that RAP and LF mimic LRP1 gene deletion
by blocking LRP1 signaling initiated by agonists produced en-
dogenously by BMDMs. LRP1 ligands are numerous and diverse
(7, 9, 14). To test our hypothesis, we treated BMDMs with an
antibody that binds to the LRP1 heavy chain (anti-LRP1) and
blocks ligand binding. Fig. 3 I–K shows that anti-LRP1 induced
expression of TNFα, IL-6, and CCL4, similarly to RAP and LF.
In control experiments, isotype-matched IgG was without effect.
Next, we studied the LRP1 agonists: α2M* (10 nM) and tPA
(12 nM). We used an enzymatically inactive tPA variant (EI-
tPA) to avoid effects unrelated to receptor-binding (26). Fig. 4A
shows that, in wild-type BMDMs, EI-tPA and α2M* significantly
decreased TNFα expression. EI-tPA and α2M* also decreased
expression of IL-6, CCL2, and CCL3 (Fig. S3 A–C). Arginase-1
mRNA was increased; TGFβ mRNA was not significantly
changed (Fig. S3 D and E). Because the basal level of expression
of proinflammatory cytokines in BMDMs was low, we tested whether
α2M* and EI-tPA attenuate the response to LPS (0.1 μg/mL).
Fig. 4 B–G shows that α2M* and EI-tPA blocked the increase in
expression of TNFα, IL-1β, IL-6, CCL2, CCL3, and CCL4 in-
duced by LPS. The activity of EI-tPA was dose dependent; the
minimum EI-tPA concentration that had a significant effect
(P < 0.05) was 0.5 nM (Fig. 4H).
To prove that the activity of EI-tPA and α2M* requires LRP1,
we used the Cre-ERT-LRP1flox/flox model system. Confirming the
mechanism of EI-tPA activity was considered particularly important
because tPA is an FDA-approved drug (27), known to bind to
receptors in addition to LRP1 (28). TAM-treated Cre-ERT-
positive BMDMs expressed increased levels of mRNA for TNFα
(Fig. 4I), IL-6, CCL3, and CCL4 (Fig. S3 F–H) as anticipated;
however, when LRP1 was deleted, EI-tPA and α2M* failed to
attenuate cytokine expression, indicating an essential role for
LRP1. Similarly, in TAM-treated Cre-ERT-LRP1flox/flox BMDMs,
RAP and LF failed to further stimulate cytokine expression (Fig.
S4), supporting the conclusion that LRP1 is the target for LF
and RAP.
NFκB Functions in the Pathway by Which LRP1 Ligands Regulate
Inflammation. When wild-type BMDMs were treated with RAP,
IκBα was phosphorylated within 5 min (Fig. 5A). Total IκBα
decreased substantially by 30 min, confirming NFκB activation.
LF also induced IκBα phosphorylation and decreased the total
abundance of IκBα (Fig. 5B). The effects of RAP and LF on
phospho-IκBα and total IκBα were sustained for 8 h (Fig. 5C).
To test whether NFκB is necessary in the pathway by which LF
and RAP increase cytokine expression in BMDMs, cells were
treated with the NFκB nuclear translocation inhibitor, JSH-23.
As a control, cells were treated with the PI3K inhibitor, LY294002.
JSH-23 blocked the increase in expression of TNFα (Fig. 5D) and
Fig. 2. LRP1 gene deletion in macrophages in vitro induces a proin-
flammatory phenotype. BMDMs from Cre-ERT-negative (control) and Cre-ERT-
positive (Cre-ERT) LRP1flox/flox mice were treated with 5 μM TAM (+) or
vehicle (−) for 7 d. (A) Cell extracts were subjected to immunoblot analysis to
detect the LRP1 β-chain and β-actin as a control for load. (B–F) RNA was
isolated and RT-qPCR was performed to quantitate mRNA for (B) TNFα,
(C) IL-6, (D) IL-1β, (E) CCL2, and (F) CCL3. (G) Cell migration was studied using
Transwell systems. Representative images of cells that migrated to the un-
derside surfaces of the membranes are shown. (H) Quantification of cell
migration results (mean ± SEM; n = 6; **P < 0.01, ***P < 0.001; one-way
ANOVA with a Tukey’s post hoc analysis).
Fig. 3. LF and RAP induce expression of proinflammatory cytokines in
BMDMs. (A–C) BMDMs from C57BL/6J mice were treated with LPS (0.1 μg/mL),
LF (150 nM), RAP expressed as a GST fusion protein (150 nM), purified GST
(150 nM), or vehicle (C) for 8 h. RT-qPCR was performed to determine mRNA
levels for TNFα, IL-6, and CCL2. (D) CCL3 mRNA was determined in BMDMs
treated for 8 h with increasing concentrations of RAP. (E) BMDMs were
stimulated for 8 h with LPS, LF, RAP, GST, or vehicle as in A. TNFα in condi-
tioned medium was determined by ELISA. (F) BMDMs were treated with LF,
RAP, or vehicle (C). Cell migration was studied using Transwell systems.
Representative images of migrated cells are shown. (G) Quantification of
cell migration results (n = 6). (H) BMDMs were treated with LF, RAP, GST
(each at 150 nM), or vehicle (C) for 8 h. Cell extracts were subjected to
immunoblot analysis to detect the LRP1 β-chain and β-actin. (I–K ) BMDMs
were treated with LRP1-neutralizing antibody (anti-LRP1) or isotype-
matched IgG for 8 h. mRNA levels were determined for TNFα, IL-6, and
CCL4 (mean ± SEM; n ≥ 6; *P < 0.05, **P < 0.01, ***P < 0.001; one-way
ANOVA followed by Dunnett’s multiple comparison test).





















CCL3 (Fig. 5E) caused by LF and RAP. LY294002 was without
effect. Fig. S5 shows that JSH-23 also blocked expression of IL-6,
IL-1β, CCL2, and CCL4.
Next, we examined the ability of LRP1 agonists to block NFκB
activation in response to LPS. Fig. 5F shows that α2M* and EI-
tPA blocked IκBα phosphorylation and the decrease in total IκB
induced by LPS treatment for 1 h. The effects of α2M* and EI-
tPA were sustained for 8 h (Fig. 5G).
LRP1 Regulates miR-155 Expression. MicroRNAs are regulators
of inflammation in various cells, including macrophages (19,
29–31). Fig. 6A shows that LRP1 gene deletion in Cre-ERT-
LRP1flox/flox BMDMs significantly increased miR-155, without
regulating miR-124, miR-9, and miR-223. In chromatin immu-
noprecipitation (ChiP) assays, association of the promoter region
of the miR-155 parent gene with RNA polymerase II was in-
creased when LRP1 was deleted (Fig. 6B), suggesting tran-
scriptional activation. The miR-9 promoter was not precipitated
at significant levels from LRP1-expressing or -deficient cells.
Treatment of LRP1-expressing BMDMs with LF or RAP for
8 h significantly increased miR-155 (Fig. 6C); however, as shown
in Fig. 6D, there was a lag phase in this response. Whereas TNFα
mRNA was elevated 1 h after adding RAP, miR-155 was not
significantly increased until 4–8 h. The increase in miR-155 was
inhibited by JSH-23, indicating an essential role for NFκB.
Because of the lag phase in miR-155 expression, we examined
the effects of inhibiting miR-155 on cytokine expression, 1 and 8 h
after adding RAP. BMDMs were transfected with 10 nMmirVANA
RNA oligonucleotide miR-155 inhibitor, which decreased miR-155
by >70%, or with control oligonucleotide. Fig. 6E shows that
inhibiting miR-155 had no effect on TNFα mRNA expression at
1 h. By contrast, TNFα expression was significantly decreased at
8 h. Similarly, miR-155 inhibition had no effect on expression
CCL4 or IL-6 at 1 h, but substantially decreased expression of
these mRNAs at 8 h (Fig. S6). These results suggest that miR-
155 plays an important role in sustaining the proinflammatory
response to LRP1 antagonists.
We considered the possibility that miR-155 was induced as a
secondary effect, downstream of cytokines such as TNFα that
were expressed at increased levels by RAP-treated BMDMs. Fig.
6F shows that TNFα-neutralizing antibody did not affect the
rapid phosphorylation of IκB in response to RAP; however,
TNFα-neutralizing antibody substantially inhibited the increase
in miR-155 observed 8 h after adding RAP (Fig. 6G).
Finally, we examined the effects of LRP1 agonists on miR-155.
Fig. 6H shows that EI-tPA and α2M* blocked the increase in
miR-155 induced by LPS. We conclude that LRP1 functions in a
ligand-specific manner to regulate miR-155.
Discussion
Despite extensive work and the availability of multiple mouse
model systems, the function of LRP1 in adult mammals re-
mains incompletely understood (9, 32). We have demonstrated
a role for macrophage LRP1 in regulating innate immunity
in vivo using a model system, LPS challenge, which directly
tests the response of the mouse to systemic activation of the
PRR, TLR4. When LRP1 was deleted in myeloid cells, the
toxicity of LPS was exacerbated and morbidity was significantly
increased. Deletion of LRP1 in vitro in BMDMs isolated from
Cre-ERT-LRP1flox/flox mice substantially increased expression
Fig. 4. α2M* and EI-tPA inhibit expression of inflammatory mediators by
BMDMs. (A) BMDMs from C57BL/6J mice were treated for 8 h with El-tPA
(12 nM), α2M* (10 nM), or vehicle (C). TNFα mRNA was determined by
RT-qPCR. (B–G) BMDMs were pretreated with LPS (0.1 μg/mL) for 30 min
and then with El-tPA (12 nM), α2M* (10 nM), or vehicle (C) for 8 h. mRNA
levels were determined for TNFα, IL-6, IL-1β, CCL2, CCL3, and CCL4.
(H) BMDMs were pretreated with LPS and then with 0.2–24 nM EI-tPA for
8 h. TNFαmRNA was determined. EI-tPA concentrations of ≥0.5 nM yielded
significant results (P < 0.05). (I) BMDMs from Cre-ERT-negative (control)
and Cre-ERT-positive (Cre-ERT) LRP1flox/flox mice were treated with TAM
(+TAM) or vehicle (−TAM) for 7 d. The Cre-ERT-negative cells and Cre-ERT-
positive cells that were not treated with TAM both expressed LRP1. The
cells were then treated with EI-tPA, α2M*, or vehicle (C) for 8 h. TNFα
mRNA was determined (mean ± SEM; n = 4; **P < 0.01, ***P < 0.001; one-
way ANOVA with Dunnett’s or Tukey’s post hoc analysis).
Fig. 5. LRP1 regulates NFκB activation. (A) BMDMs from C57BL/6J mice
were treated with 150 nM RAP for the indicated times. (B) BMDMs were
treated with vehicle (C), LPS (0.1 μg/mL), LF (150 nM), or RAP (150 nM) for
30 min. (C) The same incubations were conducted for 8 h. Immunoblot
analysis was performed to detect phospho-IκB and total IκB. (D and E)
BMDMs were pretreated with JSH-23 (10 μM), LY294002 (20 μM), or vehicle
for 16 h and then with LF, RAP, or vehicle (C) for 8 h. mRNA levels were
determined for TNFα and CCL3 (mean ± SEM; n = 6; **P < 0.01, ***P < 0.001;
one-way ANOVA with Tukey’s post hoc test). (F) BMDMs were treated with
El-tPA (12 nM) or α2M* (10 nM) together with LPS (0.1 μg/mL) or with LPS or
vehicle (C) alone for 1 h. Immunoblot analysis was performed. (G) The same
experiment was performed for 8 h.
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of multiple proinflammatory mediators. The results obtained,
using this second model of LRP1 deficiency, were consistent
with those obtained using BMDMs isolated from mLRP1−/−
mice (9–12). We conclude that LRP1 deficiency in myeloid cells
in vivo and in macrophages in vitro is proinflammatory.
In LRP1-expressing macrophages, different LRP1 ligands had
opposing effects on the activity of LRP1 as a regulator of the
macrophage inflammatory response. RAP and LF induced rapid
NFκB activation, increasing expression of the same proinflam-
matory mediators that were expressed by LRP1-deficient BMDMs.
EI-tPA and α2M* had the entirely opposite effect on BMDM
physiology, suppressing NFκB activation in response to LPS
and decreasing expression of proinflammatory mediators. In
previous studies with different cell types, RAP and LF have been
shown to competitively antagonize LRP1-dependent cellular
responses triggered by ligands like α2M* or tPA (15–17, 33–35).
We hypothesized that, under basal conditions, macrophages ex-
press one or more agonistic ligands that bind to LRP1 in an
autocrine pathway, suppressing NFκB activation. RAP and LF
would then function by inhibiting binding of these endogenously
produced agonists to LRP1. In support of this hypothesis, we
demonstrated that LRP1-specific antibody, which blocks ligand-
binding to LRP1, induces expression of inflammatory mediators
in BMDMs, similarly to LF and RAP. Because the total number
of LRP1 ligands is high (7, 9, 14), identifying LRP1 agonists that
are secreted by macrophages represents an important proteo-
mics problem for future investigation.
The antiinflammatory activity of EI-tPA and α2M* was suffi-
ciently potent to substantially inhibit and, in some cases, entirely
block cytokine expression in response to LPS. Using BMDMs
from Cre-ERT-LRP1flox/flox mice, we showed that the antiin-
flammatory activity of EI-tPA and α2M* requires LRP1. We
conclude that the antiinflammatory activity of LRP1 may be
stimulated beyond the level observed in resting macrophages by
exogenously added agonists. tPA and α2M* emerge as potentially
important antiinflammatory agents. Although α2M is abundant in
plasma, α2M circulates almost exclusively in a “nonactivated”
conformation, which does not bind to LRP1 (36). The circulating
level of tPA is about 0.1–0.2 nM (37), near the activity threshold
demonstrated in Fig. 4.
An important consequence of LRP1 gene deletion in BMDMs
was significant and selective up-regulation of miR-155. Increased
miR-155 also was observed in RAP- and LF-treated cells. In a
previous study, Baltimore and colleagues (19) applied array
technology and identified miR-155 as the major microRNA up-
regulated in macrophages in response to diverse proinflamma-
tory stimuli. miR-155 controls inflammation in mouse models of
atherosclerosis (38) and is up-regulated in synovial fluid from
patients with rheumatoid arthritis (39). When we treated BMDMs
with RAP, TNFα mRNA was increased by 1 h, whereas miR-155
was not significantly increased until 4–8 h. TNFα-neutralizing an-
tibody significantly inhibited the increase in miR-155 observed 8 h
after adding RAP. These results suggest that miR-155 expression
may be increased, at least in part, as a secondary response down-
stream of the cytokines that are expressed at increased levels when
macrophages are treated with LRP1 antagonists.
miR-155 sustained the proinflammatory activity of LRP1 an-
tagonists. Inhibiting miR-155 failed to attenuate the significant
increase in TNFα expression observed 1 h after adding RAP. By
contrast, 8 h after adding RAP, miR-155 inhibition substantially
decreased expression of TNFα, CCL4, and IL-6. These results
suggest that proinflammatory LRP1 ligands may trigger a posi-
tive feedback loop by increasing expression of cytokines such as
TNFα, which induce expression of miR-155. In turn, miR-155
promotes expression of proinflammatory mediators such as
TNFα. This type of positive feedback loop may be important in
chronic inflammation.
JSH-23 blocked the increase in miR-155 induced by RAP in
BMDMs, consistent with previous studies demonstrating that
NFκB activation promotes miR-155 expression (40, 41). In our
model system, NFκB inhibition may have inhibited transcription
of the miR-155 parent gene directly downstream of LRP1, or
expression of the cytokines that increase miR-155, or the cell-
signaling pathways activated by these cytokines. In any case,
LRP1, NFκB, and miR-155 emerge as members of a system that
may be modulated to either promote or inhibit macrophage in-
flammatory responses, depending on the continuum of LRP1
ligands present in the macrophage microenvironment.
The pathway by which LRP1 ligands regulate NFκB remains to
be completely elucidated. Although we previously demonstrated
that TNF receptor-1 (TNFR1) is increased in LRP1-deficient
fibroblasts (12, 42), TNFR1 regulation does not provide a
straightforward explanation for the activity of LRP1 ligands.
LRP1 demonstrates other important activities in macrophages
that may be critical in tissue injury and the inflammatory re-
sponse, including its function in phagocytosis of large particles (12),
Fig. 6. miR-155 sustains the proinflammatory activity of LRP1 antagonists.
(A) BMDMs from Cre-ERT-positive-LRP1flox/flox mice were treated with TAM
(+TAM) or vehicle (−TAM). miR-155, miR-124, miR-9, and miR-223 were de-
termined by qPCR (mean ± SEM; n = 5; ***P < 0.001). (B) ChIP was performed
to detect the miR-155 parent gene promoter in association with RNA poly-
merase II in BMDMs from Cre-ERT-positive-LRP1flox/flox mice treated with TAM
(+) or vehicle (−). The miR-9 promoter was analyzed as a control. (C) BMDMs
from C57BL/6J mice were treated for 8 h with LPS (0.1 μg/mL), LF (150 nM), RAP
(150 nM), GST (150 nM), or vehicle (C). miR-155 was determined (n = 5; *P <
0.05, ***P < 0.001). (D) BMDMs were treated with 150 nM RAP for the in-
dicated times. TNFα mRNA and miR-155 were determined. miR-155 also was
determined in cells treated with RAP and 10 μM JSH-23 (+JSH-23). (E) BMDMs
from C57BL/6J mice were transfected with 10 nMmiR-155 inhibitor (Inh) (+) or
with miRNA inhibitor negative control (−). After 48 h, the cells were treated
with 150 nM RAP (+) or vehicle (−) for 1 h or 8 h. TNFα mRNA was determined
(n = 4, ns, not statistically significant; *P < 0.05). (F) BMDMs were pretreated
with TNFα-neutralizing antibody (+) or isotype-matched IgG (−) and then with
RAP for 0, 30, or 60 min. Immunoblot analysis was performed. (G) BMDMs
were treated with RAP (150 nM) or vehicle (C) alone or in the presence of
TNFα-neutralizing antibody (1 μg/mL) or isotype-matched IgG for 8 h. miR-155
was determined. (H) BMDMs were treated with LPS (0.1 μg/mL) alone or to-
gether with El-tPA (12 nM) or α2M* (10 nM) for 8 h. miR-155 was determined
(n = 5; **P < 0.01, ***P < 0.001).





















efferocytosis (15, 43), and in regulating transforming growth factor-β
(44). LRP1 also is involved in antigen presentation in support of
adaptive immunity (45, 46). Understanding the integrated activity of
macrophage LRP1 in the regulation of injury and inflammation
remains an important future goal.
Materials and Methods
Proteins and Reagents. α2M was purified from plasma (47) and activated for
binding to LRP1 (α2M*) by reaction with 200 mM methylamine-HCl. α2M
modification was confirmed by nondenaturing PAGE (36). EI-tPA was from
Molecular Innovations.
Mouse Model Systems. LRP1flox/flox mice were bred with mice that express Cre
recombinase under the control of the lysozyme-M promoter (LysM-Cre), in
the C57BL/6J background, to generate mLRP1−/− mice. Littermate controls
(mLRP1+/+) were LRP1flox/flox and LysM-Cre-negative. LRP1flox/flox mice also
were bred with CreERT mice (23), which express Tam-activated Cre in all cells
(Jackson Laboratories). BMDMs were isolated from littermates that were
LRP1flox/flox and either Cre-ERT-positive or -negative. Littermates were born
at a 50:50 ratio. All experiments were approved by the University of Cal-
ifornia San Diego Institutional Animal Care and Use Committee.
For additional details on proteins and reagents, LPS challenge studies,
analyzing BMDM responses to LRP1 ligands, immunoblot analysis, miRNA
extraction and RT-PCR, gene expression analysis, Transwell cell migration
assays, ChIP assays, miRNA inhibitor studies, and statistical methods, please
see SI Materials and Methods.
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SI Materials and Methods
Proteins and Reagents. LF and Escherichia coli LPS, serotype
055.B5, were from Sigma-Aldrich. RAP was expressed as a
GST-fusion protein and purified as previously described (48).
Free GST was expressed using empty vector. GST-fusion proteins
were subjected to chromatography on Detoxi-Gel endotoxin-removing
columns (Pierce). The compound 4-hydroxytamoxifen (TAM)
was from Enzo Life Sciences. JSH-23 and LY294002 were from
Calbiochem. Rabbit TNFα-neutralizing antibody and anti-CD11b
were purchased from Abcam. Specific antibodies directed against
the C-terminal 85-kDa and the N-terminal 515-kDa subunits of
LRP1 and β-actin were from Sigma. Antibodies that detect
phosphorylated IκBα and total IκBα were from Cell Signaling
Technologies.
LPS Challenge. mLRP1−/− and mLRP1+/+ mice were treated by
i.p. injection with LPS (1 mg/kg). Control mice received an
equivalent volume of normal saline. The mice were observed for
changes in neurologic status, altered respiratory rate, and/or
hemostasis abnormalities. Those entering a moribund condition
were killed immediately by cervical dislocation under anesthesia.
Kaplan–Meier survival curves were analyzed by log-rank test
(Prism). In separate experiments, blood samples were recovered
from the retroorbital venous plexus. Plasma was isolated and
TNFα and CCL3 were measured using the mouse TNFα and
CCL3/MIP-1α Quantikine ELISA kits (R&D Systems). Lungs
and kidneys were recovered 24 h after LPS injection. RNA was
isolated and RT-qPCR was performed.
Immunohistochemistry. Lung tissue was harvested from mice,
formalin fixed, processed, and paraffin embedded. Four-micro-
meter-thick tissue sections were cut and mounted on positively
charged microscope slides. Sections were stained with antibody
against CD11b (1:1,200) from Abcam using a Ventana Discovery
Ultra (Ventana Medical Systems). Antigen retrieval was per-
formed using CC1 for 40 min at 95 °C. The primary antibody was
incubated on the sections for 1 h at 37 °C and visualized using
3,3′-diaminobenzidine as a chromagen and the UltraMap System
(Ventana Medical Systems). Slides were counterstained with
hematoxylin, rinsed, dehydrated through alcohol and xylene, and
cover slipped.
Isolation of BMDMs.The 12- to 16-wk-old mice were killed. Femurs
and tibiae were recovered from both rear legs. Bone marrow cells
were flushed from the long bones in DMEM (Invitrogen). Cell
suspensions were filtered through a 100-μm nylon cell strainer
and plated in 100-mm dishes at a density of 2 × 106 cells per dish
in DMEM containing 10% (vol/vol) FBS (HyClone Laborato-
ries) and 20% (vol/vol) L929 cell-conditioned medium. After 10 d,
nonadherent cells were removed. Adherent cells, which consti-
tuted a nearly pure population of BMDMs (2, 3), were used in
experiments.
BMDM Response to LRP1 Ligands. BMDMs from LRP1flox/flox-Cre-
ERT-positive mice and LRP1flox/flox-Cre-ERT-negative mice
were pretreated with TAM (5 μM) or with vehicle for 7 d. These
cells and cells from wild-type C57BL/6J mice were transferred to
SFM for 30 min and then treated for 8 h with α2M*, EI-tPA, LF,
or RAP. Cells were treated with LPS (0.1 μg/mL) as a control.
Treatments with vehicle or GST served as negative controls. In
another set of experiments, BMDMs from wild-type C57BL/6J
mice were transferred to SFM for 30 min and treated with rabbit
IgG1 polyclonal antibody directed against LRP1 heavy chain.
Immunoblot Analysis. Cellular extracts were prepared in RIPA
buffer (PBS with 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS) containing Complete Protease Inhibitor Mixture
(Roche Diagnostics) and sodium orthovanadate. The protein
concentration in tissue extracts was determined by bicinchoninic
acid (BCA) assay. An equivalent amount of cellular protein
(50 μg per lane) was subjected to SDS/PAGE and electro-
transferred to methanol-activated PVDF membranes. Mem-
branes were blocked with 5% (wt/vol) nonfat dry milk in 10 mM
Tris·HCl, 150 mM NaCl, pH 7.4, with 0.1% Tween 20 and
subsequently incubated with primary polyclonal antibody that
recognizes: the C-terminal 85-kDa subunit of LRP1 (1:1,000;
Sigma); phosphorylated IκB (1:1,000; Cell Signaling Technolo-
gies); total IκB (1:1,000; Cell Signaling Technologies); or
monoclonal antibody that detects actin (1:1,000; Sigma). Primary
antibody binding was detected by HRP-conjugated species-spe-
cific secondary antibodies (1:2,000; Cell Signaling Technologies).
Immunoblots were developed using enhanced chemiluminescence
ECL Plus (GE Healthcare) and HyBlot CL Autoradiography film
(Denville Scientific).
ELISAs. TNFα protein in conditioned medium was determined
using the mouse TNFα Quantikine ELISA kit (R&D Systems).
Apoptotic cell death was assessed using the Cell Death De-
tection Plus ELISA kit (Roche Diagnostics), which quantifies
apoptotic cells by detecting histone-associated DNA fragments
(mono- and oligonucleosomes).
Gene Expression Analysis. Total RNA was isolated from 40-μm-thick
sections of mouse kidneys and lungs and from BMDMs using
the acid guanidinium-thiocyanate-phenol-chloroform extraction
method (49) and TRIzol Reagent (Life Technologies). RNA was
purified using the NucleoSpin RNA kit (Macherey-Nagel) accord-
ing to the manufacturer’s instructions. cDNA was prepared using
the iScript cDNA synthesis kit (Bio-Rad). RT-qPCR was performed
using TaqMan gene expression assay products on an AB Step One
Plus Real-Time PCR system (Applied Biosystems). The relative
change in gene expression was calculated using the 2ΔΔCt method
and GAPDH gene as a standardizer. Primer-probe sets were as
follow: GAPDH (Mm99999915_g1); TNFα (Mm00443258_m1);
IL-6 (Mm00446190_m1); IL1-β (Mm00434228_m1); CCL2
(Mm00441242_m1); CCL3 (Mm00441259_g1); and CCL4
(Mm00443111_m1).
miRNA Detection. miRNA was isolated using the mirVANA
miRNA isolation kit (Applied Biosystems). miRNA (10 ng) was
retrotranscribed into cDNA using the Taqman miRNA Reverse
transcription kit (Applied Biosystems) and RT primers specific
for: miR-155, miR-9, miR-223, and miR-124. qPCR was per-
formed in duplicate using Taqman Universal PCR Master Mix,
No AmpErase UNG, and the following miRNA-specific probe
mixes (Applied Biosystems): mmu-miR-155 (002571); mmu-miR-
223–5 (007896_mat); hsa-miR-9 (000583); and mmu-miR-124a
(001182). The relative change in gene expression was calculated
using the 2ΔΔCt method and snoRNA202 (001232) as a control.
miRNA Inhibitor Studies. BMDMs isolated from C57BL/6J mice
were transfected with 10 nM miR-155 inhibitor (mmu-miR-155–
5p, Applied Biosystems) using Lipofectamine RNAiMAX Trans-
fection Reagent (Invitrogen) according to the manufacturer’s
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instructions. As positive and negative controls, cells were trans-
fected with the mirVana miRNA Inhibitor let-7c Positive Control
and mirVana miRNA Inhibitor Negative Control 1 (Ambion).
miR-155 expression was determined by qPCR to confirm de-
pletion. Subsequently, BMDMs were treated with LF or RAP,
beginning 48 h after transfection with miR-155 inhibitor.
Transwell Cell Migration Assays. BMDMs (5 × 105) were added to
the top chamber of 24-well Transwell units with 8.0-μm pores.
The underside of each membrane was coated with 10 μg/mL fi-
bronectin (Millipore). When BMDMs were pretreated with
LRP1 ligands, including RAP (150 nM) or LF (150 nM), the same
ligands were added to the medium in the Transwells. The bottom
chamber contained 10% (vol/vol) FBS. Cells were allowed to mi-
grate for 16 h. Nonmigrating cells were removed from the upper
surface. The lower surface was stained with Hema 3 (Fisher Sci-
entific). Stained membranes were imaged using a Leica DMIRE2
microscope. The number of migrated cells was determined in four
representative fields, selected by a blinded investigator, using Im-
ageJ software. Three separate membranes were analyzed for
each condition in three separate experiments.
ChIP. BMDMs (1 × 107) were treated with 0.75% formaldehyde.
Cross-linking was terminated with 0.12 M glycine. Nuclei were
isolated from cell extracts by centrifugation at 600 × g. Chromatin
was sheared into 200- to 1,000-bp fragments by sonication. Cell
debris was cleared by centrifugation and the chromatin filtered using
a 0.2-μm filter. For immunoprecipitation (IP), sheared chromatin
was incubated with anti-RNApol II antibody (Abcam), which rec-
ognizes the phospho-S-5 epitope in the C-terminal domain of
activated RNA polymerase II, for 2 h at 4 °C and Protein G-
Sepharose. DNA was eluted in 1% SDS and treated with RNase
A and Proteinase K. DNA was purified using the minElute gel
extraction kit (Qiagen). PCR was performed using Phusion
polymerase (NEB). The primers (5′-GTTTCCTTTAAGAA-
TAAAGCA-3′ and 5′-GTTCTTGGAACCTCCGGC-TCGA-3′)
amplified a region near the TATA box of the BIC gene, which
encodes miR-155.
Statistics. Statistical analysis was performed using GraphPad Prism
5.0 (GraphPad Software). All results are expressed as mean± SEM.
Survival studies were analyzed by log-rank test. ELISA results,
qPCR data, and cell migration studies were analyzed by one-way
ANOVA followed by Tukey’s or Dunnett’s post hoc analysis.
Differences between two experimental groups were evaluated us-
ing a Mann–Whitney test. In the SI figures, statistical significance is
indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. S1. LRP1 gene deletion does not compromise cell viability. BMDMs were isolated from Cre-ERT-positive-LRP1flox/flox mice and treated with 5 μM TAM
(+TAM) or vehicle (−TAM). (A) Apoptosis was measured using the Cell Death ELISA. (B) Cell viability was determined by trypan blue exclusion (mean ± SEM;
n = 4; ns, not statistically significant; Mann–Whitney test).
Fig. S2. LF and RAP increase expression of proinflammatory mediators. BMDMs from C57BL/6J mice were treated with LPS (0.1 μg/mL), LF (150 nM), RAP,
which was expressed as a GST-fusion protein (150 nM), purified GST (150 nM), or vehicle (C) for 8 h. RT-qPCR was performed to quantify mRNA levels for (A) IL-
1β and (B) CCL4 (mean ± SEM; n = 6; **P < 0.01, ***P < 0.001; one-way ANOVA followed by Dunnett’s post hoc analysis).
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Fig. S3. α2M* and EI-tPA express antiinflammatory activity by an LRP1-dependent mechanism. (A–E) BMDMs were isolated from wild-type C57BL/6J mice and
treated for 8 h with El-tPA (12 nM), α2M* (10 nM), or vehicle (C). RTqPCR was performed to determine mRNA levels for IL-6, CCL2, CCL3, Arg-1, and TGFβ (mean ±
SEM; n = 4; **P < 0.01, ***P < 0.001; one-way ANOVA with Dunnett’s post hoc test). (F–H) LRP1 was deleted in BMDMs by treating cells isolated from Cre-ERT-
positive-LRP1flox/flox mice with 5 μM TAM (+TAM) for 7 d (solid bars). LRP1-expressing BMDMs included cells isolated from Cre-ERT-negative-LRP1flox/flox mice (open
bars) and cells isolated from Cre-ERT-positive-LRP1flox/flox mice and treated with vehicle (−TAM, shaded bars). The cells were treated with EI-tPA, α2M*, or vehicle
(C) for 8 h. mRNA levels for IL-6, CCL3, and CCL4 were determined by RT-qPCR (mean ± SEM; n = 4).
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Fig. S4. RAP and LF do not further stimulate expression of proinflammatory mediators when LRP1 is deleted. LRP1 was deleted in BMDMs by treating cells
isolated from Cre-ERT-positive-LRP1flox/flox mice with 5 μM TAM (+TAM) for 7 d (solid bars). LRP1-expressing BMDMs included cells isolated from Cre-ERT-
negative-LRP1flox/flox mice (open bars) and cells isolated from Cre-ERT-positive-LRP1flox/flox mice and treated with vehicle (−TAM, shaded bars). The cells were
treated with LF (150 nM), RAP (150 nM), or vehicle (C). RT-qPCR was performed to determine expression of: (A) TNFα; (B) IL-1β; (C) CCL2; (D) CCL3; and (E) CCL4
(mean ± SEM; n = 4).
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Fig. S5. The effect of LRP1 antagonists on cytokine expression require NFкB. BMDMs were isolated from wild-type mice and pretreated for 16 h with JSH-23
(10 μM) (+) or vehicle (−) and then with LF (150 nM), RAP (150 nM), or vehicle (C) for 8 h. RNA was isolated and RT-qPCR was performed to determine mRNA
levels for (A) IL-6; (B) IL-1β; (C) CCL2; and (D) CCL4 (mean ± SEM; n = 3; *P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA with Tukey’s post hoc analysis).
Fig. S6. miR-155 sustains the antiinflammatory activity of LRP1 antagonists. BMDMs from C57BL/6J mice were transfected with miR-155 inhibitor (10 nM) (+)
or with miRNA inhibitor negative control (−). After 48 h, the cells were treated with 150 nM RAP (+) or with vehicle (−) for 1 h or 8 h. mRNA levels for (A) IL-6
and (B) CCL4 were determined by RT-qPCR (mean ± SEM; n = 4; ***P < 0.001; ns, not statistically significant; one-way ANOVA followed by Tukey’s post hoc
analysis).
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